Navigation Links
aTyr Pharma Secures $23M Financing From Top Tier Venture Investor
Date:10/26/2010

program heading to the clinic, Tmax, for treating thrombocytopenia, will serve as our first proof of concept for this exciting class of protein-based therapeutics."

As part of the financing Dr. James C. Blair will serve as a Director for the company, joining current board members Mr. John Clarke, Dr. David Mack, Dr. John Mendlein, Dr. Amir Nashat, Dr. Paul Schimmel and Dr. Jeff Watkins.

About Physiocrines

Physiocrines are a new class of extracellular proteins that modulate signaling pathways in a variety of physiological processes.  Physiocrines are derived from tRNA synthetases, which function intracellularly, and thus were overlooked by genomic discovery efforts.  These endogenous human proteins have a broad range of activities and act through a variety of receptor classes, via mechanisms distinct from current pharmaceuticals, and have applications relevant to a number of therapeutic areas ranging from immunology and hematology to metabolism disorders.

About aTyr Pharma

aTyr Pharma develops biologic therapeutics based on physiocrines, and is currently focusing on developing products to improve patient care in immune, metabolic, and hematologic indications.  aTyr Pharma has established a dominant intellectual property estate surrounding physiocrine based compositions and therapeutic applications. The company's leading program, Tmax, is in preclinical development.  The privately held biotech was founded by Dr. Paul Schimmel, a leading aminoacyl tRNA synthetase scientist and biotechnology entrepreneur, and John Clarke from Cardinal Partners.  aTyr Pharma is backed by leading life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information please visit www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500
2. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
3. A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge
4. Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology
5. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
6. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
7. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
8. Lotus Pharmaceuticals Announces New Patent for Controlled-Release Diabetes Drug
9. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
10. ANGIOTECH PHARMACEUTICALS ANNOUNCES CONFERENCE CALL AND WEBCAST
11. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... 2015 , ... Production of high tenacity filament yarn of viscose rayon (excluding ... For instance, it surpassed the EUR 106 million mark (in value terms) in 2013, ... a major producer, while Italy is a key consumer. , The high tenacity ...
(Date:7/27/2015)... -- According to the new Market Research Report ... by Application (Biobanking, Regenerative Medicine, Drug Discovery), by Geography ( ... Asia-Pacific , Rest of the World) - ... was valued at $247.7 million in 2014, which is estimated ... CAGR of 18.2% between 2014 and 2019. Browse ...
(Date:7/26/2015)... ... July 26, 2015 , ... Maine Standards Company, LLC ... linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and Vitamin B12 ... the CLSI recommended “equal delta” method for linearity testing and is liquid, ready-to-use. ...
(Date:7/24/2015)... HACKENSACK, N.J. , July 24, 2015  Champions ... of advanced technology solutions and services to personalize the ... will report its financial and operational results for the ... 2015, on Tuesday, July 28, 2015, before market open. ... to discuss the results that day at 9:00 a.m. ...
Breaking Biology Technology:High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2
... , ... CEO, Matthew Sarad, plans a series of experiments to demonstrate the power of nanotechnology ... ... Mr. Matthew Sarad, has announced plans to attempt to rejuvenate living animals with advanced ...
... HORSHAM, Pa., Sept. 10 Centocor Ortho Biotech Products, L.P. ... U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug ... in combination with docetaxel for the treatment of women with ... Centocor Ortho Biotech is evaluating the FDA,s letter and ...
... , ABBOTT PARK, Ill. and MENLO ... announced today a definitive agreement to acquire the outstanding equity of ... minimally invasive repair of cardiac mitral valves. The acquisition provides ... for structural heart disease, in which physicians use catheter-based devices to ...
Cached Biology Technology:Matthew Sarad to Reverse Aging and Cure Cancer 2Matthew Sarad to Reverse Aging and Cure Cancer 3Matthew Sarad to Reverse Aging and Cure Cancer 4Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 2Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 3Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 4Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 5Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 2Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 3Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 4
(Date:6/25/2015)... 2015  Imagine a tool specifically designed to help ... life. That,s exactly what USANA,s True Health Assessment ... portable health program provides a personalized approached to measuring ... your lifestyle and nutrition. At the ... night, USANA,s THA was honored with the Industry Innovation ...
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... Systems market, over the next six years. It contains ... affect the industry, along with their impact from the ... It also discusses the industry, market, and technology ... expected that the need of concerned authorities to efficiently ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Resources, one of the world,s leading research and advisory ... most of the biomarker-drug success stories are in oncology, ... chronic conditions, and their use in clinical trials of ... report entitled Driving Drug and Diagnostic R&D: ...
... 2013 -- Researchers have identified some of the underlying physics ... a stall in midflight -- unlike conventional fixed wing aircraft, ... The analysis, in which the researchers studied the ... how insects fly and informs the design of small flying ...
... 2013 A bicoastal group of scientists at Sanford-Burnham ... grant from the U.S. Department of the Air Force ... chemicals. The goal of the project is to provide ... a rapid, cost-effective manner. "The current approach to ...
Cached Biology News:Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing 2Sanford-Burnham receives US Air Force grant to perform next-generation toxicity screens 2
NORMAL DONOR DONKEY SERUM...
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Mouse Serpin F1/PEDF MAb (Clone 199315)...
Biology Products: